Category Archives: Health
Latest From Health
The term “rare disease” may be misleading: to be “rare” a disease must effect fewer than 200,000 people in the U.S., but there are over 7,000 rare diseases that have been identified. Taken together, that means that nearly 30 million Americans suffer from a rare disease or condition. While innovative therapies have been developed for a variety of these diseases—including Sickle Cell Anemia, Gaucher Disease, and Huntington Disease—too many patients still lack treatment options. Developing Read More >
Check out California Life Sciences Association (CLSA) president and chief executive officer Sara Radcliffe’s op-ed that ran in The Sacramento Bee this week. She precisely lays out the concerns and challenges associated with delivering cutting-edge medical therapies to patients.
In a hearing held on Thursday to review the Department of Health and Human Services 2017 budget, Senate Finance Committee Chairman Orrin Hatch (R-UT) pressed HHS Secretary Sylvia Burwell on whether or not the Obama Administration is planning to issue an executive order that would allow the government to negotiate drug prices. Read more in the Washington Examiner. Video of Thursday’s hearing can be found on the Senate Finance Committee website.
New York Senator Chuck Schumer joined attendees at the 2016 BIO CEO & Investor Conference this afternoon for a fireside chat, moderated by BIO Chairman Ron Cohen, to discuss current political and public policy issues facing the country and the biopharmaceutical industry. The Senator expressed optimism that progress can be made on a bipartisan basis in a number of areas that will be conducive to investment in medical innovation and the well-paying jobs that such Read More >
Check out today’s Wall Street Journal Editorial, highlighting why you can’t make medical progress by punishing medical advances. The editorial highlight’s how political attacks on the innovation ecosystem undermine the ability to bring important advances to patients. It notes that new initiatives, such as the Administration’s cancer “moonshot,” will be less likely to find success if short-sighted politicians create “investment uncertainty” that will drive away private capital away from the biopharmaceutical sector.” Read more in Read More >